Get In Touch
Have any questions or comments about the content you see on this page?
Our News
February 20, 2019
Alnylam has been named a Fast Company World's 50 Most Innovative Company for 2019, number 3 in the Biotech category and number 32 overall. We are incredibly honored to have been recognized by Fast Company for our innovation in developing RNAi (RNA interference) therapeutics as a new class of medicines.
From Fast Company:
"Alnylam became the first company to bring an RNA interference (RNAi) treatment to market, winning FDA approval for its drug Onpattro in August 2018. The culmination of a 16-year quest to realize the promise of Nobel-winning research, Onpattro treats..." You can read more from Fast Company here.
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site